What is Advair?
Advair is GlaxoSmithKline's (GSK) branded inhaler combining fluticasone propionate (corticosteroid) and salmeterol (long-acting beta agonist, or LABA) for asthma and COPD. It comes in Diskus (dry powder) and HFA (metered-dose) forms, with strengths like 100/50 mcg, 250/50 mcg, and 500/50 mcg.[1]
What is Wixela?
Wixela Inhub is Mylan (now Viatris)'s generic version of Advair Diskus, approved by the FDA as interchangeable with the branded Diskus. It uses identical active ingredients (fluticasone propionate/salmeterol) in the same strengths and dry powder delivery.[1][2]
Key Differences
Wixela matches Advair Diskus exactly in formulation, dosing, and device mechanics—no differences in efficacy, safety, or pharmacokinetics per FDA interchangeability.[2] Main distinctions:
- Cost: Wixela costs 70-90% less (often $100-200/month vs. Advair's $400-600 without insurance).[3]
- Availability: Advair Diskus faces shortages; Wixela fills gaps as the first interchangeable generic (approved 2019).[2]
- Branding: Advair has HFA version (not replicated by Wixela); Wixela is Diskus-only.
No patent issues block Wixela; GSK's key Advair Diskus patents expired 2019, enabling generics.4
How Do They Compare in Real Use?
Patients report identical feel, inhalation technique, and counter display. Switch success rate exceeds 90% in studies, with no increased exacerbations.[2] Wixela avoids Advair's black-box LABA warning differences post-approval updates.
Who Makes Them and Availability?
- Advair: GSK (U.S. sales ~$1B/year pre-generic).
- Wixela: Viatris (Mylan/Viatris).
Both prescription-only; Wixela widely stocked at pharmacies like CVS, Walgreens.[3]
Cost Savings and Insurance
| Scenario | Advair Diskus (30-day) | Wixela Inhub (30-day) |
|----------|-------------------------|-----------------------|
| Cash Price | $450-650 | $150-250 |
| With Coupon | $300-400 | $50-100 |
| GoodRx Avg. | $450 | $140 |
Insurance often prefers Wixela; copays drop to $20-50 vs. $100+ for brand.[3]
[1]: FDA Orange Book (fda.gov)
[2]: FDA Approval Letter for Wixela (fda.gov, Jan 2019)
[3]: GoodRx.com pricing data (2024)